Worsening of motor features of parkinsonism with olanzapine.
Identifieur interne : 007677 ( Main/Merge ); précédent : 007676; suivant : 007678Worsening of motor features of parkinsonism with olanzapine.
Auteurs : E S Molho [États-Unis] ; S A FactorSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1999.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (adverse effects), Antipsychotic Agents (administration & dosage), Antipsychotic Agents (adverse effects), Benzodiazepines, Female, Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Male, Middle Aged, Motor Skills (drug effects), Neurologic Examination (drug effects), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (diagnosis), Pirenzepine (administration & dosage), Pirenzepine (adverse effects), Pirenzepine (analogs & derivatives), Psychoses, Substance-Induced (diagnosis), Psychoses, Substance-Induced (drug therapy), Risk Factors.
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Antipsychotic Agents, Levodopa, Pirenzepine.
- chemical , adverse effects : Antiparkinson Agents, Antipsychotic Agents, Levodopa, Pirenzepine.
- chemical , analogs & derivatives : Pirenzepine.
- chemically induced : Parkinson Disease, Secondary.
- diagnosis : Parkinson Disease, Parkinson Disease, Secondary, Psychoses, Substance-Induced.
- drug effects : Motor Skills, Neurologic Examination.
- drug therapy : Parkinson Disease, Psychoses, Substance-Induced.
- Aged, Aged, 80 and over, Benzodiazepines, Female, Humans, Male, Middle Aged, Risk Factors.
Abstract
Clozapine is the current treatment of choice for drug-induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new "atypical" antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.
PubMed: 10584679
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004086
- to stream PubMed, to step Curation: 004086
- to stream PubMed, to step Checkpoint: 004070
- to stream Ncbi, to step Merge: 000165
- to stream Ncbi, to step Curation: 000165
- to stream Ncbi, to step Checkpoint: 000165
Links to Exploration step
pubmed:10584679Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Worsening of motor features of parkinsonism with olanzapine.</title><author><name sortKey="Molho, E S" sort="Molho, E S" uniqKey="Molho E" first="E S" last="Molho">E S Molho</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Albany Medical College, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Albany Medical College, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Factor, S A" sort="Factor, S A" uniqKey="Factor S" first="S A" last="Factor">S A Factor</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1999">1999</date><idno type="RBID">pubmed:10584679</idno><idno type="pmid">10584679</idno><idno type="wicri:Area/PubMed/Corpus">004086</idno><idno type="wicri:Area/PubMed/Curation">004086</idno><idno type="wicri:Area/PubMed/Checkpoint">004070</idno><idno type="wicri:Area/Ncbi/Merge">000165</idno><idno type="wicri:Area/Ncbi/Curation">000165</idno><idno type="wicri:Area/Ncbi/Checkpoint">000165</idno><idno type="wicri:doubleKey">0885-3185:1999:Molho E:worsening:of:motor</idno><idno type="wicri:Area/Main/Merge">007677</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Worsening of motor features of parkinsonism with olanzapine.</title><author><name sortKey="Molho, E S" sort="Molho, E S" uniqKey="Molho E" first="E S" last="Molho">E S Molho</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Albany Medical College, New York, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Albany Medical College, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Factor, S A" sort="Factor, S A" uniqKey="Factor S" first="S A" last="Factor">S A Factor</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1999" type="published">1999</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antipsychotic Agents (administration & dosage)</term><term>Antipsychotic Agents (adverse effects)</term><term>Benzodiazepines</term><term>Female</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (diagnosis)</term><term>Pirenzepine (administration & dosage)</term><term>Pirenzepine (adverse effects)</term><term>Pirenzepine (analogs & derivatives)</term><term>Psychoses, Substance-Induced (diagnosis)</term><term>Psychoses, Substance-Induced (drug therapy)</term><term>Risk Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Antipsychotic Agents</term><term>Levodopa</term><term>Pirenzepine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Antipsychotic Agents</term><term>Levodopa</term><term>Pirenzepine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Pirenzepine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term><term>Parkinson Disease, Secondary</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Benzodiazepines</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clozapine is the current treatment of choice for drug-induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new "atypical" antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007677 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007677 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:10584679
|texte= Worsening of motor features of parkinsonism with olanzapine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:10584679" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |